BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. USO
4. SPY
5. SRRK
6. DFTX
7. AZN
8. CGEM
9. SATL
10. LYNX

Go back to BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
(NASDAQ: BBIO) Delayed: 73.06 +0.62 (0.86%)
Previous Close $72.44    52 Week High $ 
Open $72.55    52 Week Low $ 
Day High $73.67    P/E N/A 
Day Low $72.21    EPS $ 
Volume 503,273